全文获取类型
收费全文 | 2740篇 |
免费 | 195篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 107篇 |
妇产科学 | 21篇 |
基础医学 | 353篇 |
口腔科学 | 41篇 |
临床医学 | 276篇 |
内科学 | 392篇 |
皮肤病学 | 31篇 |
神经病学 | 289篇 |
特种医学 | 269篇 |
外国民族医学 | 1篇 |
外科学 | 358篇 |
综合类 | 96篇 |
一般理论 | 1篇 |
预防医学 | 271篇 |
眼科学 | 13篇 |
药学 | 200篇 |
中国医学 | 3篇 |
肿瘤学 | 204篇 |
出版年
2022年 | 26篇 |
2021年 | 42篇 |
2020年 | 29篇 |
2019年 | 38篇 |
2018年 | 52篇 |
2017年 | 36篇 |
2016年 | 60篇 |
2015年 | 65篇 |
2014年 | 70篇 |
2013年 | 115篇 |
2012年 | 107篇 |
2011年 | 91篇 |
2010年 | 59篇 |
2009年 | 64篇 |
2008年 | 111篇 |
2007年 | 129篇 |
2006年 | 117篇 |
2005年 | 93篇 |
2004年 | 84篇 |
2003年 | 79篇 |
2002年 | 87篇 |
2001年 | 84篇 |
2000年 | 69篇 |
1999年 | 73篇 |
1998年 | 52篇 |
1997年 | 43篇 |
1996年 | 42篇 |
1995年 | 45篇 |
1994年 | 29篇 |
1993年 | 41篇 |
1992年 | 68篇 |
1991年 | 66篇 |
1990年 | 58篇 |
1989年 | 52篇 |
1988年 | 69篇 |
1987年 | 47篇 |
1986年 | 68篇 |
1985年 | 43篇 |
1984年 | 38篇 |
1983年 | 42篇 |
1982年 | 27篇 |
1981年 | 29篇 |
1980年 | 23篇 |
1979年 | 29篇 |
1977年 | 24篇 |
1976年 | 19篇 |
1975年 | 17篇 |
1974年 | 25篇 |
1973年 | 17篇 |
1971年 | 15篇 |
排序方式: 共有2953条查询结果,搜索用时 15 毫秒
991.
Ladenstein R Pötschger U Hartman O Pearson AD Klingebiel T Castel V Yaniv I Demirer T Dini G;EBMT Paediatric Working Party 《Bone marrow transplantation》2008,41(Z2):S118-S127
Between 1978 and 2006, the European Group for Blood and Marrow Transplantation registered 4098 high-dose therapy (HDT) procedures followed by stem cell rescue (SCR) (3974 autologous/124 allogeneic) in patients with neuroblastoma. The 5-year rates for overall (OS) and event-free survival are 37 and 32%, respectively. The median age at diagnosis is 3.9 years (0.3-62 years) with 76 patients older than 18 years. Patients above 10 years carry a 2.5-fold higher risk. Younger patients cure significantly (<0.001) better with OS rates of 40 and 30% for age groups 2-4 years and 4-10 years, respectively. Their risks are about twofold higher than that of patients below 2 years with OS rates of 60%. The better the quality of remission status before HDT/SCT the better are the observed OS rates: 43% in CR1 (1199 patients) and 42% for CR2 (140 patients), and 36% for those in very good partial or partial remission (1413 patients) and 21% for those with sensitive relapse (134 patients). Patients reported with stable disease in first remission still had an OS rate of 30%. Multivariate analysis shows significantly better OS in the age group of less than 2 years (<0.0001), as well as a better quality of remission status before HDT/SCT (P<0.0001), with the use of peripheral stem cells (P=0.014), autologous SCT (P=0.031) and busulphan/melphalan HDT (P<0.001). Busulphan/melphalan HDT/SCT in first remission achieves an OS of 48%, while it is only 35% with other regimens (P<0.001), including melphalan alone, other melphalan-containing regimens, a variety of other drugs given as a single HDT as well as the addition of TBI or sequential HDT/SCT procedures. Further progress in the field may only be expected from large-scale international randomized trials. 相似文献
992.
Giordano TP Morgan RO Kramer JR Hartman C Richardson P White CA Suarez-Almazor ME El-Serag HB 《Journal of general internal medicine》2006,21(6):613-617
BACKGROUND: Disparities in survival for black patients with HIV in the United States have been reported. The VA is an equal access health care system. OBJECTIVE: To determine whether such disparities are present in the VA health care system. DESIGN: Retrospective cohort study using national VA administrative databases. PATIENTS: Two thousand three hundred and four white and 3,641 black HIV-infected patients first hospitalized for HIV between October 1, 1996 and September 30, 2000. MEASUREMENTS: Thirty-day mortality after first hospitalization with HIV, and subsequent long-term survival. Follow-up ended at death or September 30, 2002. Data were adjusted for age, sex, HIV disease severity, non-HIV-related comorbidities, primary discharge diagnosis, hepatitis C status, and facility effects. RESULTS: The mean follow-up was 3.2 years. Overall survival was similar for black patients compared with white patients (adjusted hazard ratio 1.09, P=.09). Hospital mortality was 7.0% for black and 6.4% for white patients (P=.35). Adjusted hospital mortality for black patients was similar to that of white patients (odds ratio 1.20, P=.10). Long-term survival after hospitalization did not significantly differ by race (adjusted hazard ratio 1.07, P=.21, for black patients compared with white patients). CONCLUSIONS: Survival during and after first hospitalization with HIV in the VA did not significantly differ for white and black patients, possibly indicating similar effectiveness of care for HIV. Further research is needed to understand the reasons for the lack of disparities for VA patients with HIV and whether the VA's results could be replicated. 相似文献
993.
Freedman RJ Aziz N Albanes D Hartman T Danforth D Hill S Sebring N Reynolds JC Yanovski JA 《The Journal of clinical endocrinology and metabolism》2004,89(5):2248-2253
Uncontrolled trials have reported significant weight gain in women with breast cancer during treatment with adjuvant chemotherapy. We prospectively evaluated body composition before (visit 1), immediately after (visit 2), and 6 months after (visit 3) chemotherapy in 20 women with stages I-IIIA breast cancer [body mass index (BMI): 24.1 +/- 3.9 kg/m(2)]. We compared their weight change to 51 age- and BMI-matched healthy controls (BMI: 25.5 +/- 3.8 kg/m(2)). In women with breast cancer, there was no weight change from visit 1-2, or from visit 1-3, but weight increased from visit 2-3 (+1.09 +/- 2.46 kg; P = 0.05). Weight change was not different from controls during either interval. In the breast cancer group, the percentage of body fat assessed by air displacement plethysmography increased, and fat-free mass decreased from visit 1-2 (+2.3 +/- 4% and -2.2 +/- 4%; P = 0.02) and from visit 1-3 (+4.0 +/- 6% and -3.8 +/- 6%; P = 0.01). By dual energy x-ray absorptiometry, the percentage of body fat increased from visit 2-3 (+0.9 +/- 1.6%; P = 0.02). Bone mineral content decreased from visit 2-3 (-0.02 +/- 0.04 kg; P = 0.02) and from visit 1-3 (-0.04 +/- 0.06 kg; P = 0.005). By computed tomography, the visceral adipose to sc adipose tissue ratio decreased from visit 1-3 (-0.02 +/- 0.05 ml; P = 0.02). We conclude that, compared with controls, women with breast cancer receiving modern adjuvant chemotherapy regimens show no significant changes in weight during the first year of their treatment. They do, however, appear to undergo unfavorable changes in body composition. 相似文献
994.
Henson SW Burke D Crow SM Hartman SJ 《JONA'S healthcare law, ethics and regulation》2005,7(4):114-118
As in any other industry, laws and regulations significantly impact the functioning of the healthcare industry. Some laws, such as those relating to malpractice and social insurance systems, affect the manner in which the industry operates. Other laws, such as those regulating antitrust and employment practices, affect the organization and the environment in which the industry operates. It is increasingly important that practitioners and managers be cognizant of this complex and dynamic legal minefield. This study examined healthcare managers and executives' knowledge of 9 key issues in the legal and regulatory environment of the healthcare industry. Specifically, the study focused on knowledge concerning tort and contract liability, insurance law, labor and employment regulation, criminal and ethical responsibility, antitrust regulation, the law governing business associations and recent developments. Findings suggest that the levels of knowledge required to manage legal and regulatory issues are much greater than the existing levels of knowledge. 相似文献
995.
Miller WL Hartman KA Burritt MF Borgeson DD Burnett JC Jaffe AS 《Clinical chemistry》2005,51(3):569-577
BACKGROUND: Objective methods to assess the adequacy of medication therapy for patients with advanced heart failure are lacking. Serial measurements of biomarkers might be beneficial. Therapy guided by N-terminal pro-B-type natriuretic peptide (NT-proBNP) might be helpful because NT-proBNP should be lowered by therapies that decrease endogenous BNP secretion. METHODS: NT-proBNP and BNP were measured in a nonconsecutive patient cohort receiving clinically indicated intravenous nesiritide. Blood samples were drawn before, at 6 and 24 h during, and at 6 h after infusion. A reduction in NT-proBNP was defined as a decrease from baseline during infusion ("infusion responders") of >3 SD of the variability of the assay measurement (approximately 20%). Patients with decreases >20% in both NT-pro BNP and BNP at 6 h post infusion were designated "biochemical responders". RESULTS: Forty patients [27 males; mean (SE) age, 68 (2) years; mean (SE) left ventricular ejection fraction, 25 (1.4)%] were studied. All patients improved clinically. Overall, the changes in NT-proBNP were a 18 (4.6)% [mean (SE)] and 19.8% (median) decrease from baseline at 24 h of infusion and a 22 (6.0)% and 17.8% decrease at 6 h post infusion (P <0.001 compared with baseline). In a large number of patients, decreases in NT-proBNP were, however, within the variability of the assay. Subgroup analysis showed that 22 of 40 patients were infusion responders with a >20% decrease from baseline in NT-proBNP during nesiritide infusion, whereas only 12 patients were biochemical responders with >20% decreases from baseline postinfusion for both NT-proBNP and BNP. CONCLUSIONS: In this study, many patients had decreased NT-proBNP and BNP values after therapy with nesiritide, but the majority of patients did not demonstrate biochemically significant decreases in analytes despite a clinical response. Until we know more about the responses of natriuretic peptides to therapies such as nesiritide, a strategy of monitoring NT-proBNP and BNP to guide therapy cannot be universally advocated. 相似文献
996.
Lowes BD Shakar SF Metra M Feldman AM Eichhorn E Freytag JW Gerber MJ Liard JF Hartman C Gorczynski R Evans G Linseman JV Stewart J Robertson AD Roecker EB Demets DL Bristow MR 《Journal of cardiac failure》2005,11(9):53-669
BACKGROUND: Chronic heart failure is a disease syndrome characterized in its advanced stages by a poor quality of life, frequent hospitalizations, and a high risk of mortality. In advanced and ultra-advanced chronic heart failure, many treatment options, such as cardiac transplantation and mechanical devices, are severely limited by availability and cost. Short-term Phase II clinical trials suggest that low-dose oral inotropic therapy with enoximone may improve hemodynamics and exercise capacity, without adversely affecting mortality, in selected subjects with advanced chronic heart failure. Based on these data, the ability of enoximone to deliver safe and efficacious palliative treatment of advanced/ultra-advanced chronic heart failure is being evaluated in Phase III clinical trials. METHODS AND RESULTS: The Enoximone Clinical Trials Program is a series of 4 clinical trials designed to evaluate the safety and efficacy of oral enoximone in advanced chronic heart failure. ESSENTIAL I and II (The Studies of Oral Enoximone Therapy in Advanced Heart Failure) will investigate the effects of oral enoximone on all-cause mortality and cardiovascular hospitalization, submaximal exercise capacity, and quality of life in subjects with New York Heart Association Class III/IV chronic heart failure. EMOTE (Oral Enoximone in Intravenous Inotrope-Dependent Subjects) will evaluate the potential of oral enoximone to wean subjects with ultra-advanced chronic heart failure from chronic intravenous inotropic therapy to which they have been shown to be dependent. EMPOWER (Enoximone Plus Extended-Release Metoprolol Succinate in Subjects with Advanced Chronic Heart Failure) will explore the potential of enoximone to increase the tolerability of continuous release metoprolol in subjects shown previously to be hemodynamically intolerant to beta-blocker treatment. CONCLUSION: These studies are Phase III, multicenter, randomized, double-blinded, placebo-controlled trials designed to test the general hypothesis that chronic oral administration of low doses of enoximone can produce beneficial effects in subjects with advanced or ultra-advanced chronic heart failure. 相似文献
997.
Paul TL Chiam MBBS MRCP Howard A Cohen MD Carlos E. Ruiz MD PhD 《Catheterization and cardiovascular interventions》2008,71(4):564-567
Percutaneous closure of sedundum atrial septal defects (ASD) has been shown to be safe and effective. Usually crossing the defect is relatively straightforward. Occasionally, with fenestrated ASDs, trying to cross the defect(s) may be challenging. We report the use of a “paralle wire” (0.018 or 0.014 inch wire) technique to maintain access and be able to recross the same defect easily in case of misplacement until just before the device was secured and released. This technique could be used also as a “body wire” for large ASDs with deficient rims to reduce the incidence of device prolapse, and for patent foramen ovale and ventricular septal defect closures. This is a simple and easily reproducible method with the equipment readily available in virtually all catheterization laboratories. © 2008 Wiley‐Liss, Inc. 相似文献
998.
Paco M. J. Welsing Johan L. Severens Margriet Hartman Piet L. C. M. van Riel Roland F. J. M. Laan 《Arthritis care & research》2004,51(6):964-973
Objective
To determine the cost effectiveness of treatment strategies for rheumatoid arthritis patients satisfying the indication for tumor necrosis factor (TNF)‐blocking treatment.Methods
A Markov model study was performed. The following treatment strategies were considered: 1) usual treatment; 2) treatment with leflunomide, in the case of nonresponse after 3 months, switch to usual treatment; 3) TNF‐blocking treatment, in the case of nonresponse after 3 months, switch to usual treatment; 4) treatment with leflunomide, in the case of nonresponse, switch to TNF‐blocking treatment, in the case of nonresponse to TNF‐blocking treatment, switch to usual treatment; 5) TNF‐blocking treatment, in the case of nonresponse, switch to leflunomide treatment, in the case of nonresponse to leflunomide, switch to usual treatment. Expected patient‐years in the different Markov states, costs, and quality‐adjusted life years (QALYs) were compared between the treatment strategies; incremental cost‐effectiveness ratios (ICERs) were calculated.Results
Over the 5‐year period, the expected effect on disease activity and QALYs was better for treatment strategies that included TNF‐blocking treatment than for the other treatment strategies. The greater effectiveness of these treatment strategies reduced medical and nonmedical costs compared with usual treatment by about 16% and 33%, respectively, omitting the costs of medication. When the costs of medication were included, the costs of strategies that started with TNF‐blocking treatment were higher than those of the other treatment strategies. Treatment strategy 4 had the most favorable ICER of the treatment strategies that included TNF‐blocking treatment: €163,556/QALY compared with usual treatment.Conclusion
Among strategies that include TNF‐blocking agents, one starting with leflunomide and, in the case of nonresponse, switching to TNF‐blocking treatment probably results in the most favorable ratio between incremental costs and effects.999.
R Kneen MD Nguyen T Solomon NG Pham CM Parry TT Nguyen TL Ha A Taylor TT Vo TT Nguyen NP Day NJ White 《Clinical infectious diseases》2004,39(11):1591-1598
BACKGROUND: Despite the availability of antitoxin and antibiotics, the mortality rate for diphtheria remains high, mostly because of cardiac complications. METHODS: During 1 year, 154 Vietnamese children with diphtheria admitted to a referral hospital were studied prospectively with clinical examination, including a simple pseudomembrane score, 12-lead and 24-hour electrocardiography, measurement of serum cardiac enzyme levels, and estimation of troponin T levels. RESULTS: Thirteen children had diphtheritic cardiomyopathy on admission, and 19 developed it subsequently. Twelve children (8%) died. The combination of pseudomembrane score of >2 and bull neck predicted the development of diphtheritic cardiomyopathy, with a positive predictive value of 83% and a negative predictive value of 93%. Administration of 24-hour electrocardiography on admission improved the ability to predict diphtheritic cardiomyopathy by 57%. Fatal outcome was best predicted by the combination of myocarditis on admission and a pseudomembrane score of >2. Of the cardiac enzyme levels measured, an elevated aspartate aminotransferase level was the best predictor. The presence of troponin T identified additional children with subclinical cardiac damage. CONCLUSIONS: The development of diphtheritic cardiomyopathy can be predicted by means of simple measures. 相似文献
1000.
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study 下载免费PDF全文
J Jao W Yu K Patel TL Miller B Karalius ME Geffner LA DiMeglio A Mirza JS Chen M Silio EJ McFarland RB Van Dyke D Jacobson the Pediatric HIV/AIDS Cohort Study Adolescent Master Protocol study 《HIV medicine》2018,19(3):175-183